Quirós QML

Language: Spanish
References: 13
Page: 515-518
PDF size: 148.82 Kb.

ABSTRACT

Endometrial cancer is the most common gynecologic malignancy in several countries. The atypical endometrial hyperplasia is the endometrial cancer precursor, with a risk of 54% to develop the malignancy and a risk of 50% of coexistence. The definitive treatment of atypical hyperplasia requires total hysterectomy; however, the finding of this pathology in reproductive age has done necessary the use of conservative techniques, wich have demostrated that they constitutes an alternative to manage this entity in selected cases.

REFERENCES

1. Armstrong A. Diagnosis and management of endometrial hyperplasia. The Journal of Minimally Invasive Gynecology. 2012; 19: 562-571.

2. Costales A, et al. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecologic Oncology. 2014; 135: 451-454.

3. Gallos ID. Ofinran O, Shehmar M, Coomarasamy A, Gupta JK. Current management of endometrial hyperplasia –a survey of United Kingdom consultant gynaecologits. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2011; 158: 305-307.

4. Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrelreleasing intrauterine system for endometrial hiperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010; 203: 547.e1- 10.

5. Kimura T, et al. Clinical over- and under- estimation in patients who underwent hysterectomy for atypical endometrial hyperplasia diagnosed by endometrial biopsy: the predictive value of clinical parameters and diagnostic imaging. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2003; 108: 213–216.

6. Leitao MM Jr, Kehoe S, Barakat RR, et al. Endometrial sampling diagnosis of FIGO grade I endometrial adenocarcinoma with a background of complex atypical hyperplasia and final hysterectomy pathology. Am J Obstet Gynecol. 2010; 202: 278.e1-6.

7. Miller C, Bidus MA, Pulcini JP, et al. The ability of endometrial biopsies with atypical complex hyperplasia to guide surgical management. AM J Obstet Gynecol. 2008; 199: 69.e1.

8. Morotti M, et al. Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Gynecologic Oncology. 2012; 125: 536-540.

9. Simpson A, et al. Fertility sparing treatment of complex atypical hyperplasia and lowgrade cáncer using oral progestin. Gynecologic Oncology. 2014; 133: 229-233.

10. Sivridis E, Giatromanolaki A. Demystifying endometrial hyperperplasia. Diagnostic Histopathology. 2013; 19(7): 223- 230.

11. Whyte JS, Gurney EP, Curtin JP, et al. Lymph node dissection in the surgical management of atypical endometrial hyperplasia. Am J Obstet Gynecol. 2010; 202: 176.e1- 4.

12. Wildermeersch D, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with levonorgestrel-releasing intrauterine system: Long term follow-up. Maturitas. 2007; 57: 210- 213.

13. Zeferino-Toquero M, Bañuelos- Flores J, et al. Incidencia de cáncer de endometrio en pacientes de hiperplasia endometrial Ginecol Obstet Mex. 2013; 81: 519-524.